BAY 358535

Drug Profile

BAY 358535

Alternative Names: BAY 171998

Latest Information Update: 04 Nov 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celera Genomics Group
  • Class Antiasthmatics
  • Mechanism of Action Mast cell tryptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 04 Nov 1998 Discontinued-Preclinical for Asthma (Inhalation)
  • 20 Oct 1998 BAY 171998 is now called BAY 358535
  • 31 Aug 1998 No-Development-Reported for Asthma (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top